Perrigo Amends & Restates Credit Agreement, Securing $1.0B Revolving Facility Until 2031
Summary
Perrigo has amended and restated its credit agreement, securing a new $1.0 billion revolving credit facility with an extended maturity to 2031 and maintaining a $972.4 million term loan B facility, providing critical liquidity and financial flexibility.
Key Events
-
Amended & Restated Credit Agreement
Perrigo Company plc entered into an Amended and Restated Credit Agreement on March 20, 2026, replacing an existing agreement from April 20, 2022.
-
New Credit Facilities Established
The agreement establishes a $1.0 billion revolving credit facility maturing on March 20, 2031, and maintains a $972.4 million term loan B facility maturing on April 20, 2029.
-
Refinancing of Existing Debt
Proceeds from the new revolving facility will be used to prepay existing Term A Loans in their entirety.
-
Improved Borrowing Terms
The amendment eliminates the credit spread adjustment applicable to loans under the Revolving Facility, potentially reducing borrowing costs.
Analysis
Perrigo has amended and restated its credit agreement, establishing a new $1.0 billion revolving credit facility maturing in March 2031 and maintaining a $972.4 million term loan B facility. This is a significant development for the company, especially in light of its reported $1.43 billion net loss for 2025 and anticipated further impairments. The extension of the revolving facility's maturity provides crucial liquidity and extends the company's financial runway, addressing near-term capital structure risks. The elimination of the credit spread adjustment for the revolving facility also suggests more favorable borrowing terms. The proceeds will be used for refinancing existing Term A Loans, working capital, and general corporate purposes, which are vital for a company navigating financial challenges.
At the time of this filing, PRGO was trading at $9.69 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.